Research focuses on chronic myeloid leukemia with the goal of creating a new therapy for patients Study funded by Robert & Lynda Carter Altman Family Foundation Research Fund LOS ANGELES--(BUSINESS ...

The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

Chronic myeloid leukaemia (CML) is a clonal haematopoietic stem cell disorder driven by the BCR–ABL fusion gene, which produces a constitutively active tyrosine kinase. This aberrant protein fosters ...

Scemblix outperformed standard tyrosine kinase inhibitor treatment in patients with Philadelphia chromosome-positive chronic myeloid leukemia. Frontline Scemblix (asciminib) improved outcomes over ...

Finding a cure for a rare type of blood cancer could be accelerated by a new virtual platform that allows researchers easy access to data from patient samples generated by laboratories around the ...

Please provide your email address to receive an email when new articles are posted on . Jorge Cortes, MD, received Society of Hematologic Oncology’s Michael J. Keating Outstanding Achievement Award.

Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an analysis of ELVN stock now.

If the name of leukemia specialist Jorge Cortes, MD, appears any more often in PubMed, they’ll need to name a wing after him. Jorge Cortes, MD Over 30 years, Cortes has led or co-authored hundreds of ...